Can I Take St. John's Wort with Spironolactone?

Spironolactone (brand names Aldactone and CaroSpir) is an FDA-approved aldosterone antagonist used at higher doses for hypertension, edema, and heart failure, and prescribed off-label at lower doses (typically 50-200 mg/day) by dermatologists and gynecologists for hormonal acne, hirsutism, and PCOS-related androgen excess. St. John's Wort (Hypericum perforatum) is an herbal supplement most often taken for mild-to-moderate mood symptoms.

No dedicated pharmacokinetic trial appears to have directly measured what happens to spironolactone blood levels when St. John's Wort is added. What is established, from decades of pharmacology research on St. John's Wort in general, is that it is one of the strongest known herbal inducers of the CYP3A4 liver enzyme, and spironolactone is metabolized substantially through that same enzyme. On mechanism alone, taking the two together is a reasonable-to-avoid combination, not a confirmed one, and this article treats it that way.

The direct answer

Combining St. John's Wort with spironolactone is not recommended, based on established CYP3A4 induction pharmacology for St. John's Wort and spironolactone's known reliance on CYP3A4 metabolism, even though no interaction trial has isolated this specific drug pair. The plausible clinical consequence is reduced spironolactone and canrenone (its active metabolite) exposure, which could show up as acne relapse, higher blood pressure than expected, or reduced antiandrogen effect in hirsutism, rather than as an acute safety event. This is a pharmacokinetic interaction, not a pharmacodynamic one, so it develops over days to weeks rather than immediately, and dose timing does not fix it.

How the two drugs are believed to interact

Spironolactone undergoes extensive first-pass metabolism in the liver and gut wall. Its active metabolites, principally canrenone, are largely responsible for its clinical effect, and their formation and clearance depend heavily on CYP3A4 activity. Spironolactone's oral bioavailability is already variable (commonly cited in the range of roughly 60-90% depending on formulation and food), which leaves room for an enzyme inducer to meaningfully lower blood levels rather than a drug that is already close to fully absorbed.

The active constituent in St. John's Wort responsible for most known drug interactions is hyperforin. Hyperforin activates the pregnane X receptor (PXR), a nuclear receptor that upregulates transcription of the CYP3A4 gene in the liver and intestine. This PXR-CYP3A4 mechanism is well established in the pharmacology literature and is the reason St. John's Wort is widely used as a reference "strong inducer" in drug-interaction study design, including in regulatory guidance on in vitro drug interaction testing, which is generally understood to recognize St. John's Wort among agents considered potent clinical CYP3A4 inducers (confirm current wording directly with the relevant regulatory guidance before relying on this for a specific regulatory claim).

Separately, hyperforin has also been reported to induce P-glycoprotein (P-gp), an intestinal efflux transporter that can push absorbed drug back into the gut before it reaches the bloodstream. If spironolactone or its metabolites are meaningful P-gp substrates, this would be a second, additive route to lower exposure. This specific point needs verification against the primary pharmacology literature before it is stated as settled for spironolactone.

CYP3A4 induction from St. John's Wort is generally described as taking roughly one to two weeks of regular use to develop and a similar span (on the order of two to four weeks) to wear off after stopping, because it depends on new enzyme protein being made and then turned over, not on how much drug is circulating at a given moment. That timeline is a reasonable planning assumption but the exact days should not be treated as a precise, individually applicable number.

Evidence-status interaction assessment

Why timing the doses apart does not help

This is worth stating plainly because it is a common assumption. Chelation-type interactions (for example, calcium or iron binding a drug in the gut) can sometimes be managed by spacing doses several hours apart. Enzyme induction is different: once CYP3A4 protein levels rise from regular St. John's Wort use, the elevated enzyme activity is present around the clock, independent of when either substance was last taken. Spacing the doses within the same day does not reduce total daily induction. The only way to remove the effect is to stop the inducing agent and allow enzyme levels to fall back over the following weeks.

Where the risk is most consequential

The clinical stakes differ by why someone is taking spironolactone.

Hormonal acne (typically 50-100 mg/day). At the lower end of the dosing range used for acne, a meaningful drop in canrenone exposure could plausibly bring drug levels below what is needed to suppress androgen receptor activity in the skin, which could look like "spironolactone stopped working" when the real driver is an added inducer. This is a reasonable clinical hypothesis based on the pharmacology, not a confirmed finding specific to acne outcomes.

Heart failure and hypertension (spironolactone as part of guideline-directed therapy). In heart failure with reduced ejection fraction, spironolactone is part of an evidence-based regimen with mortality benefit established in randomized trial evidence (the RALES trial, published in the New England Journal of Medicine in 1999, is the landmark study in this area; confirm the exact effect size against the primary paper before quoting a specific number). Any unrecognized reduction in drug exposure in this population is a more serious concern than in acne, because the endpoint is survival, not cosmetic improvement.

Hirsutism and PCOS. Spironolactone is commonly used as an antiandrogen in PCOS management. Professional guideline bodies in this space generally advise caution with agents that strongly induce drug-metabolizing enzymes; the exact wording of the current guideline should be checked directly rather than relied on secondhand.

If the combination is already happening

• Do not increase the spironolactone dose on your own to compensate. If induction is present, an empirical dose increase can become excessive once the inducer's effect wears off after stopping it.
• Tell the prescribing clinician, and bring the supplement bottle so the exact product and any stated hyperforin content can be reviewed.
• A reasonable follow-up window is about four to six weeks after stopping St. John's Wort, checking whichever endpoint matters for that patient: acne lesion count, blood pressure, hirsutism scoring, or an androgen panel where relevant.
• For patients on spironolactone for heart failure or hypertension, a basic metabolic panel (potassium, creatinine) is a reasonable general check if a reduced potassium-sparing effect is a concern, though this has not been specifically documented for this drug pair.

Low-hyperforin products are not a confirmed workaround

Some St. John's Wort products are marketed as lower in hyperforin content specifically to reduce drug-interaction risk. Lower-hyperforin extracts have been associated with less CYP3A4 induction in some pharmacokinetic research on other drug pairs. That does not establish safety with spironolactone specifically, and most over-the-counter U.S. products are standardized to hypericin content rather than hyperforin content, so the actual hyperforin level is often not disclosed on the label. Until product-specific and drug-specific data exist, avoidance of the combination is the more conservative approach.

Supplement options with no known enzyme-induction concern

Patients looking for mood support or general supplementation while on spironolactone have several options that are not known PXR/CYP3A4 activators: vitamin D, omega-3 fatty acids, zinc, and magnesium are commonly used in dermatology and general wellness contexts without a described enzyme-induction interaction with spironolactone. This is a general statement about mechanism, not a claim that these supplements have been proven to help acne or mood in a way equivalent to St. John's Wort; specific efficacy claims for each should be evaluated separately. For depressive symptoms that led someone to St. John's Wort in the first place, discussing a formal evaluation or an SSRI with a prescribing clinician is a more evidence-grounded path than substituting a different unregulated botanical.

Disclosing supplement use matters

Research on prescription-supplement co-use has repeatedly found that a substantial share of patients do not disclose over-the-counter supplement use to their physician, on the general assumption that "natural" products do not interact with prescription drugs. That assumption is the core problem with this specific pairing: the interaction risk here comes entirely from pharmacology, not from anything unusual about either product's safety profile in isolation.

What is established, what is plausible, and what is not established

Established: St. John's Wort is a strong, well-characterized inducer of CYP3A4 through PXR activation. Spironolactone's clinical effect depends substantially on CYP3A4-mediated metabolism of the parent drug into active metabolites. Enzyme induction is a systemic, time-dependent effect that dose separation cannot fix.

Plausible but unproven for this specific pair: That St. John's Wort meaningfully lowers spironolactone or canrenone blood levels in practice, and that this translates into measurable loss of acne, hirsutism, or blood pressure control. No dedicated pharmacokinetic study of this pair was identified.

Not established: Any specific percentage reduction in spironolactone exposure, any specific safety data for low-hyperforin St. John's Wort products combined with spironolactone, and any specific effect on serum potassium from this combination at typical acne-treatment doses.

Seek urgent care rather than waiting for a routine follow-up if a person on spironolactone develops symptoms of low potassium suppression reversal (such as swelling, palpitations, or marked blood pressure elevation) or symptoms of heart failure decompensation (worsening shortness of breath, rapid weight gain, leg swelling); these warrant prompt clinical evaluation regardless of supplement history.